193 related articles for article (PubMed ID: 32595096)
1. Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials.
Yu HJ; Kaiser PK; Zamora D; Bocanegra M; Cone C; Brown DM; Sadda SR; Wykoff CC
Ophthalmol Retina; 2021 Mar; 5(3):224-233. PubMed ID: 32595096
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment.
Baker CW; Josic K; Maguire MG; Jampol LM; Martin DF; Rofagha S; Sun JK;
Ophthalmology; 2023 May; 130(5):533-541. PubMed ID: 36521571
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis).
Kaiser PK
Trans Am Ophthalmol Soc; 2009 Dec; 107():311-24. PubMed ID: 20126505
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
7. Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials: Implications for Clinic-Based Outcomes.
Salabati M; Huang C; Kamalipour A; Yu HJ; Mahmoudzadeh R; Jeng-Miller K; Chen E; Shah CP; Wykoff CC; Hsu J
Ophthalmol Sci; 2024; 4(2):100372. PubMed ID: 37868803
[TBL] [Abstract][Full Text] [Related]
8. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
[TBL] [Abstract][Full Text] [Related]
9. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
[TBL] [Abstract][Full Text] [Related]
11. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity.
Busch C; Okada M; Zur D; Fraser-Bell S; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Degenhardt V; Loewenstein A; Iglicki M; Rehak M;
Acta Ophthalmol; 2020 Nov; 98(7):e801-e806. PubMed ID: 32115886
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Retinal Layer Thickness in Eyes with Resolved Diabetic Macular Edema Receiving Ranibizumab with Normal Eyes.
Rentiya ZS; Kherani S; Usmani B; Qazi MA; Sadiq MA; Iftikhar M; Nguyen QD; Shah SM; Sepah YJ;
Ophthalmologica; 2020; 243(1):27-36. PubMed ID: 31747663
[TBL] [Abstract][Full Text] [Related]
14. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
[TBL] [Abstract][Full Text] [Related]
15. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG
Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
17. Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab Monotherapy for Central Retinal Vein Occlusion: A Randomized Clinical Trial.
McAllister IL; Smithies LA; Chen FK; Mackey DA; Sanfilippo PG
JAMA Ophthalmol; 2018 Dec; 136(12):1391-1397. PubMed ID: 30347030
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM
JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion.
Lloyd Clark W; Liu M; Kitchens J; Wang PW; Haskova Z
BMC Ophthalmol; 2019 Jan; 19(1):11. PubMed ID: 30621653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
